Skip to main content

Pharmacogenetics

  • Chapter
  • First Online:
Textbook of Personalized Medicine
  • 1469 Accesses

Abstract

Pharmacogenetics, a term recognized in pharmacology in the pre-genomic era, is the study of the influence of genetic factors on action of drugs as opposed to genetic causes of disease. Now, it is the study of the linkage between the individual’s genotype and the individual’s ability to metabolize a foreign compound. The pharmacological effect of a drug depends on pharmacodynamics (interaction with the target or the site of action) and pharmacokinetics (absorption, distribution and metabolism). It also covers the influence of various factors on these processes. Drug metabolism is one of the major determinants of drug clearance and the factor that is most often responsible for interindividual differences in pharmacokinetics. Pharmacogenetics links genotype and phenotype as shown in Fig. 4.1. The differences in response to medications are often greater among members of a population than they are within the same person or between monozygotic twins at different times. The existence of large differences with small variability among patients is consistent with inheritance as a determinant of drug response. It is estimated that genetics can account for 20–95% of variability in drug disposition and effects. Genetic polymorphisms in drug-metabolizing enzymes, transporters, receptors, and other drug targets have been linked to interindividual differences in the efficacy and toxicity of many medications. Although interindividual variations in drug response result from effects of age, sex, disease or drug interactions, genetic factors represent an important influence in drug response and efficacy and remain constant throughout life. This has led to the recognition of the discipline “pharmacogenetics” since the 1950s, which can be viewed as an integration of gene profiling and pharmaceutical chemistry. From this initial definition, the scope has broadened so that it overlaps with pharmacogenomics.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Ingelman-Sundberg M (2008) Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. N Engl J Med 358:637–639

    Article  CAS  PubMed  Google Scholar 

  • Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C (2007) Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 116:496–526.

    Google Scholar 

  • McDowell SE, Coleman JJ, Ferner RE (2006) Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 332:1177–1181

    Article  CAS  PubMed  Google Scholar 

  • Mega JL, Close SL, Wiviott SD et al (2009) Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354–362

    Article  CAS  PubMed  Google Scholar 

  • Reynolds KK, Valdes R, Hartung BR, Linder LW (2007) Individualizing warfarin therapy. Personal Med 4:11–31

    Article  CAS  Google Scholar 

  • Simon T, Verstuyft C, Mary-Krause M et al (2009) Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360:363–375

    Article  CAS  PubMed  Google Scholar 

  • Sissung TM, Mross K, Steinberg SM et al (2006) Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenias. Eur J Cancer 42:2893–2896

    Article  CAS  PubMed  Google Scholar 

  • Takeuchi F, McGinnis R, Bourgeois S et al (2009) A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 5:e1000433.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Kewal K. Jain .

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Jain, K.K. (2009). Pharmacogenetics. In: Textbook of Personalized Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0769-1_4

Download citation

Publish with us

Policies and ethics